REG - Allergy Therapeutics - First Patient Dosed in G308 Paediatric Trial

Allergy TherapeuticsAnnouncement

27/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241127:nRSa7432Na&default-theme=true

RNS Number : 7432N  Allergy Therapeutics PLC  27 November 2024

 

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

Allergy Therapeutics announces first patient treated in G308 Phase III trial
to evaluate long-term efficacy and safety of Grass MATA MPL in paediatric
patients

 

-       Industry first long-term subcutaneous allergen-specific
immunotherapy trial in paediatric subjects with grass induced allergic
rhinitis

 

27 November 2024 Allergy Therapeutics (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies,
announces that the first subject has been treated in the Phase III G308 trial
to evaluate the long-term efficacy and safety of Grass MATA MPL in paediatric
subjects.

 

Grass MATA MPL incorporates MicroCrystalline Tyrosine adsorbed allergoids and
the adjuvant Monophosphoryl-lipid A ("MPL"). This innovative technology only
requires patients to receive six doses prior to the grass allergy season.

 

Treatment initiation in the G308 paediatric trial follows, as previously
announced, the completion
(https://www.londonstockexchange.com/news-article/AGY/g306-grass-phase-iii-trial-meets-primary-endpoint/16207998)
of the Group's pivotal Phase III G306 trial in adults and subsequent
submission
(https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=16289598)
of Marketing Authorisation Application to the Paul Ehrlich Institut in
Germany. Grass MATA MPL has demonstrated a highly statistically significant
and clinically relevant reduction in the Combined Symptom & Medication
Score compared to placebo over the peak pollen season in adults and the G308
trial is designed to evaluate long-term efficacy and safety in a paediatric
population.

 

Manuel Llobet, CEO of Allergy Therapeutics, commented: "The start of the
Phase III G308 trial investigating the efficacy and safety of our Grass MATA
MPL in a paediatric population marks an exciting step in bringing this
innovative treatment to further patients affected by grass allergies. Building
on our successful adult trials, this study will help us understand how our
short-course immunotherapy can benefit children affected by grass allergies,
potentially transforming their treatment journey."

 

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please see
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

About Grass MATA MPL

Grass MATA MPL is being developed as a subcutaneous immunotherapy product for
the treatment of allergic rhinitis and/or rhinoconjunctivitis.

 

Grass MATA MPL contains an extract of 13 grass pollens modified with
glutaraldehyde to form allergoids that reduces the reactivity with
immunoglobulin E (IgE) antibodies without a reduction in other important
immunological properties, such as T-cell reactivity. The allergoid is adsorbed
to microcrystalline tyrosine as a depot adjuvant system formulation.
Monophosphoryl lipid-A (MPL), is included as an adjuvant to increase the
immunogenic effect of the immunotherapy and to enhance the switch from an
allergen specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1)
like immune response.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFLFVRLDLRFIS